In order to identify other potential metabolic targets for T-ALL beyond HK2 that would preferentially inhibit leukemia while sparing lymphocytes, we compared in vivo proliferating T cells and primary mouse T-ALL cells by RNA-seq. This evidence concerns the gene HK2 and leukemia.